Video

Dr. Biran on 2-Year Update of Immunotherapy Triplet in High-Risk Multiple Myeloma

Author(s):

Noa Biran, MD
Conference|ASH Annual Meeting and Exposition

Noa Biran, MD, physician, John Theurer Cancer Center, discusses the 2-year update of a phase II trial of pembrolizumab (Keytruda), lenalidomide (Revlimid), and dexamethasone as post-autologous stem cell transplant consolidation in patients with high-risk multiple myeloma.

Noa Biran, MD, physician, John Theurer Cancer Center, discusses the 2-year update of a phase II trial of pembrolizumab (Keytruda), lenalidomide (Revlimid), and dexamethasone as post-autologous stem cell transplant consolidation in patients with high-risk multiple myeloma.

<<< View more from the 2019 ASH Annual Meeting

Related Videos
J. Bradley Elder, MD
Rimas V. Lukas, MD
Diane Reidy-Lagunes, MD, vice chair, Oncology Operations, Regional Care Network, Memorial Sloan Kettering Cancer Center
Yelena Y. Janjigian, MD, chief, Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center
Paolo Caimi, MD
Jennifer Scalici, MD
Steven H. Lin, MD, PhD
Anna Weiss, MD, associate professor, Department of Surgery, Oncology, associate professor, Cancer Center, University of Rochester Medicine
Roy S. Herbst, MD, PhD, Ensign Professor of Medicine (Medical Oncology), professor, pharmacology, deputy director, Yale Cancer Center; chief, Hematology/Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital; assistant dean, Translational Research, Yale School of Medicine
Victor Moreno, MD, PhD
Related Content
peterschreiber.media– stock.adobe.com
November 23rd 2024

Vorasidenib Shows Consistent Efficacy With Manageable Safety in IDH1/2-Mutant Diffuse Glioma

Stephen Liu, MD; Sara A. Hurvitz, MD, FACP; S. Vincent Rajkumar, MD; Sumanta Kumar Pal, MD, FASCO; Shubham Pant, MD, MBBS
May 23rd 2024

Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting

Michael Badruddoja, MD
November 23rd 2024

NanO2 Plus Radiation/Temozolomide Is Under Exploration in Newly Diagnosed Glioblastoma

Paul G. Richardson, MD
October 2nd 2023

Richardson Reviews Findings and Future Directions With Mezigdomide Plus Dexamethasone in R/R Myeloma

Syed Abbas Ali, MBBS
November 22nd 2024

Bispecific Antibodies and CAR T-Cell Therapies Continue to Reshape Myeloma Treatment Landscape

David R. Oveisi, MD
November 20th 2024

Expanded Indications for CAR T-Cell Therapies Shepard in New Era of Myeloma Care